A research letter in The Lancet suggests that users of high-dose rofecoxib were 1·7 times more likely than non-users to have coronary heart disease (CHD); and among new users, this rate increased to 1·93 times. By contrast, there was no evidence of raised risk of CHD
among users of rofecoxib at doses of 25 mg or less or among users of other NSAIDs. Researchers conducted a retrospective cohort study of individuals on the expanded
Tennessee Medicaid programme (TennCare) between Jan 1999, and June 2001, to assess the occurrence of serious CHD in non-users (n=202,916) and in users of rofecoxib and other NSAIDs (rofecoxib n=24,132, other n=151,728). Participants were aged 50-84 years, lived in the community, and had no life-threatening non-cardiovascular illness
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!